-+ 0.00%
-+ 0.00%
-+ 0.00%

Zymeworks Presents Data On Six Poster Presentations Regarding New Preclinical Data From Its Antibody-Drug Conjugate, Payload Development Programs At American Association For Cancer Research Annual Meeting 2026

Benzinga·04/17/2026 19:04:36
Listen to the news

Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced six poster presentations featuring new preclinical data from its antibody-drug conjugate (ADC) and payload development programs at the American Association for Cancer Research (AACR) Annual Meeting 2026.